Zhongguo Yi Xue Ke Xue Yuan Xue Bao
Department of Vascular Surgery, PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
Published: August 2020
Oral anticoagulants play an important role in the prevention and treatment of thromboembolic diseases.Warfarin,a traditional oral anticoagulant,is limited in clinical use due to its limitations such as narrow therapeutic window and requirements on frequent monitoring and dose adjustment.Direct oral anticoagulants(DOACs)such as dabigatran,rivaroxaban,apixaban,and edoxaban are increasingly used to prevent and treat venous thrombosis or thrombus formation.However,recent studies have documented inter-individual variability in plasma drug levels of DOACs.This article summarizes the recent advances in the pharmacogenomics of DOACs.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3881/j.issn.1000-503X.11423 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.